Binding of small molecules to an adaptive protein–protein interface

Understanding binding properties at protein–protein interfaces has been limited to structural and mutational analyses of natural binding partners or small peptides identified by phage display. Here, we present a high-resolution analysis of a nonpeptidyl small molecule, previously discovered by medicinal chemistry [Tilley, J. W., et al. (1997) J. Am. Chem. Soc. 119, 7589–7590], which binds to the cytokine IL-2. The small molecule binds to the same site that binds the IL-2 α receptor and buries into a groove not seen in the free structure of IL-2. Comparison of the bound and several free structures shows this site to be composed of two subsites: one is rigid, and the other is highly adaptive. Thermodynamic data suggest the energy barriers between these conformations are low. The subsites were dissected by using a site-directed screening method called tethering, in which small fragments were captured by disulfide interchange with cysteines introduced into IL-2 around these subsites. X-ray structures with the tethered fragments show that the subsite-binding interactions are similar to those observed with the original small molecule. Moreover, the adaptive subsite tethered many more compounds than did the rigid one. Thus, the adaptive nature of a protein–protein interface provides sites for small molecules to bind and underscores the challenge of applying structure-based design strategies that cannot accurately predict a dynamic protein surface.

[1]  W. DeGrado,et al.  Complementarity of Combinatorial Chemistry and Structure-Based Ligand Design: Application to the Discovery of Novel Inhibitors of Matrix Metalloproteinases , 1996 .

[2]  B. Pan,et al.  Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor. , 2002, Journal of molecular biology.

[3]  W. Stites,et al.  Protein−Protein Interactions: Interface Structure, Binding Thermodynamics, and Mutational Analysis , 1997 .

[4]  G. Ju,et al.  Localization in human interleukin 2 of the binding site to the alpha chain (p55) of the interleukin 2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Pflugrath,et al.  The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.

[6]  R. Stroud,et al.  Site-directed ligand discovery. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Chothia,et al.  The atomic structure of protein-protein recognition sites. , 1999, Journal of molecular biology.

[8]  Jan Tavernier,et al.  Molecular cloning of human interleukin 2 cDNA and its expression in E. coli , 1983, Nucleic Acids Res..

[9]  A. Cochran,et al.  Protein-protein interfaces: mimics and inhibitors. , 2001, Current opinion in chemical biology.

[10]  H. Wolfson,et al.  Access the most recent version at doi: 10.1110/ps.21302 References , 2001 .

[11]  W. Sebald,et al.  Mutant proteins of human interleukin 2. Renaturation yield, proliferative activity and receptor binding. , 1989, European journal of biochemistry.

[12]  K. P. Murphy,et al.  Configurational effects in antibody–antigen interactions studied by microcalorimetry , 1995, Proteins.

[13]  S. Atwell,et al.  Structural plasticity in a remodeled protein-protein interface. , 1997, Science.

[14]  Enrico A. Stura,et al.  Functional Mimicry of a Protein Hormone by a Peptide Agonist: The EPO Receptor Complex at 2.8 Å , 1996, Science.

[15]  T. Honjo,et al.  Molecular cloning of cDNA encoding human interleukin-2 receptor , 1984, Nature.

[16]  W. Delano,et al.  Convergent solutions to binding at a protein-protein interface. , 2000, Science.

[17]  D. Rich,et al.  Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. , 2002, Journal of medicinal chemistry.

[18]  Peter Ertl,et al.  Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease. 2. Potency and chirality. , 2002, Journal of medicinal chemistry.

[19]  I D Campbell,et al.  The solution structure of the F42A mutant of human interleukin 2. , 1995, Journal of molecular biology.

[20]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[21]  R. Stroud,et al.  Structure and specific binding of trypsin: comparison of inhibited derivatives and a model for substrate binding. , 1974, Journal of molecular biology.

[22]  T. Taniguchi,et al.  Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.

[23]  R. Karlsson,et al.  A thermodynamic characterization of the binding of thrombin inhibitors to human thrombin, combining biosensor technology, stopped-flow spectrophotometry, and microcalorimetry. , 2002, Analytical biochemistry.

[24]  K. Flaherty,et al.  Definition and spatial location of mouse interleukin‐2 residues that interact with its heterotrimeric receptor. , 1993, The EMBO journal.

[25]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[26]  T. Kunkel Rapid and efficient site-specific mutagenesis without phenotypic selection. , 1985, Proceedings of the National Academy of Sciences of the United States of America.